These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 8630236

  • 1. 5alpha-reductase inhibitors/finasteride.
    Stoner E.
    Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
    [Abstract] [Full Text] [Related]

  • 2. Maintenance of clinical efficacy with finasteride therapy for 24 months in patients with benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E.
    Arch Intern Med; 1994 Jan 10; 154(1):83-8. PubMed ID: 7505563
    [Abstract] [Full Text] [Related]

  • 3. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ, Miner M.
    Clin Ther; 2007 Jan 10; 29(1):17-25. PubMed ID: 17379044
    [Abstract] [Full Text] [Related]

  • 4. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.
    McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, Albertsen P, Roehrborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J.
    N Engl J Med; 1998 Feb 26; 338(9):557-63. PubMed ID: 9475762
    [Abstract] [Full Text] [Related]

  • 5. Finasteride in the treatment of benign prostatic hyperplasia.
    Ekman P, Andersen JT, Wolf H.
    Acta Urol Belg; 1996 Mar 26; 64(1):IX-XII. PubMed ID: 8659328
    [Abstract] [Full Text] [Related]

  • 6. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
    Boudon C, Lobaccaro JM, Lumbroso S, Lechevallier E, Mottet N, Gibelin B, Sultan C.
    Cell Mol Biol (Noisy-le-grand); 1995 Dec 26; 41(8):1007-15. PubMed ID: 8747081
    [Abstract] [Full Text] [Related]

  • 7. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O, Oishi K, Okada Y, Mizutani Y, Itokawa Y, Tomoyoshi T, Okada K, Komatz Y, Matsuda T, Takeuchi H.
    Hinyokika Kiyo; 1996 Apr 26; 42(4):323-31. PubMed ID: 8693970
    [Abstract] [Full Text] [Related]

  • 8. The effect of finasteride on prostate specific antigen: review of available data.
    Guess HA, Gormley GJ, Stoner E, Oesterling JE.
    J Urol; 1996 Jan 26; 155(1):3-9. PubMed ID: 7490873
    [Abstract] [Full Text] [Related]

  • 9. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity.
    Helfand BT, Blackwell RH, McVary KT.
    J Urol; 2010 Jul 26; 184(1):218-23. PubMed ID: 20483154
    [Abstract] [Full Text] [Related]

  • 10. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia.
    Roehrborn CG, Bruskewitz R, Nickel JC, McConnell JD, Saltzman B, Gittelman MC, Malek GH, Gottesman JE, Suryawanshi S, Drisko J, Meehan A, Waldstreicher J, Proscar Long-Term Efficacy and Safety Study Group.
    J Urol; 2004 Mar 26; 171(3):1194-8. PubMed ID: 14767299
    [Abstract] [Full Text] [Related]

  • 11. [Medical treatment of benign prostatic hyperplasia. The efficacy of finasteride depends on prostatic volume].
    Granados Loarca EA.
    Arch Esp Urol; 1999 Apr 26; 52(3):201-8. PubMed ID: 10371735
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study.
    Anwarul Islam AK, Kashem MA, Shameem IA, Kibria SA.
    Bangladesh Med Res Counc Bull; 2005 Aug 26; 31(2):54-61. PubMed ID: 16967810
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia.
    Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C, ARIA3001, ARIA3002 and ARIB3003 Study Investigators.
    Eur Urol; 2004 Oct 26; 46(4):488-94; discussion 495. PubMed ID: 15363566
    [Abstract] [Full Text] [Related]

  • 14. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H, Lan O, Poulain JE, Comenducci A.
    Prog Urol; 2005 Dec 26; 15(6):1090-5. PubMed ID: 16429658
    [Abstract] [Full Text] [Related]

  • 15. [Finasteride (Proscar) for benign prostatic hypertrophy].
    Matzkin H, Chen J, Braf Z.
    Harefuah; 1993 Dec 15; 125(12):453-6, 496. PubMed ID: 7509305
    [Abstract] [Full Text] [Related]

  • 16. [Long-term results of proscar (finasteride, MSD) treatment of patients with benign prostatic hyperplasia].
    Tkachuk VN, Al'-Shukri SKh, Kornienko VI, Kuz'min IV.
    Urol Nefrol (Mosk); 1998 Dec 15; (4):37-9. PubMed ID: 9727320
    [Abstract] [Full Text] [Related]

  • 17. [The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia].
    Djavan B, McConnell J.
    Wien Med Wochenschr; 1996 Dec 15; 146(8):165-8. PubMed ID: 8767401
    [Abstract] [Full Text] [Related]

  • 18. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
    Span PN, Völler MC, Smals AG, Sweep FG, Schalken JA, Feneley MR, Kirby RS.
    J Urol; 1999 Jan 15; 161(1):332-7. PubMed ID: 10037433
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evaluation of men on finasteride.
    Gormley GJ.
    Semin Urol Oncol; 1996 Aug 15; 14(3):139-44. PubMed ID: 8865475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.